Viveve Medical (VIVE) Upgraded at ValuEngine
Viveve Medical (NASDAQ:VIVE) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Friday.
VIVE has been the topic of a number of other reports. Mizuho assumed coverage on shares of Viveve Medical in a report on Thursday, November 16th. They set a “buy” rating and a $10.00 target price on the stock. Cowen set a $11.00 target price on shares of Viveve Medical and gave the stock a “buy” rating in a report on Monday, October 23rd. Northland Securities assumed coverage on shares of Viveve Medical in a report on Friday, January 5th. They set an “outperform” rating and a $8.00 target price on the stock. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating on shares of Viveve Medical in a report on Thursday, January 4th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $10.00.
Shares of Viveve Medical (VIVE) opened at $4.24 on Friday. The stock has a market cap of $82.37, a P/E ratio of -1.97 and a beta of -0.67. Viveve Medical has a fifty-two week low of $3.75 and a fifty-two week high of $11.16. The company has a current ratio of 3.89, a quick ratio of 3.63 and a debt-to-equity ratio of 2.72.
A number of institutional investors have recently added to or reduced their stakes in VIVE. Neuberger Berman Group LLC acquired a new stake in shares of Viveve Medical in the 3rd quarter valued at $419,000. TIAA CREF Investment Management LLC acquired a new stake in shares of Viveve Medical in the 2nd quarter valued at $296,000. ING Groep NV raised its holdings in shares of Viveve Medical by 93.7% in the 3rd quarter. ING Groep NV now owns 325,000 shares of the company’s stock valued at $1,703,000 after purchasing an additional 157,200 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Viveve Medical by 135.4% in the 2nd quarter. Vanguard Group Inc. now owns 450,142 shares of the company’s stock valued at $3,232,000 after purchasing an additional 258,912 shares in the last quarter. Finally, Numeric Investors LLC acquired a new stake in shares of Viveve Medical in the 2nd quarter valued at $330,000. Institutional investors own 66.89% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Viveve Medical (VIVE) Upgraded at ValuEngine” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/viveve-medical-vive-upgraded-at-valuengine/1838070.html.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.